LOVASTATIN EFFECT ON VASCULAR REMODELING AND MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
https://doi.org/10.20996/1819-6446-2008-4-4-18-22
Abstract
Aim. To study effect of 12-month therapy with lovastatin on vascular remodeling, systolic and diastolic functions of left ventricle (LV).
Material and methods. 84 patients (54,3±6,5 y.o.) with ischemic heart disease (IHD) and dislipoproteinemia were involved in the study. Patients were randomized into 2 groups. Patients of the 1st group (n=44) received lovastatin (20-60 mg daily) in addition to hypolipidemic diet and standard therapy. Patients of the 2nd group (n=39) were treated with diet and standard therapy only. Lipid spectrum and transaminase blood levels estimation, carotid duplex ultrasonography, echocardiography were performed initially and after 12 months of treatment.
Results. Decrease of carotid intima-media thickness, delay of increasing of LV myocardium mass index, increase of LV ejection fraction was observed in 12 months of treatment in patients of the 1st group. There were not any changes of LV diastolic function in both groups.
The conclusion. In patients with IHD and dislipoproteinemia 12 month lovastatin therapy prevents of vascular remodeling and improves LV systolic function.
About the Authors
A. S. Kerimkulova
Kyrgyz State Medical Academy, Akhunbaeva ul. 92, Bishkek, 720020 Kyrgyz Republic
Kyrgyzstan
Kyrgyzstan
A. M. Noruzbaeva
Kyrgyz State Medical Academy, Akhunbaeva ul. 92, Bishkek, 720020 Kyrgyz Republic
Kyrgyzstan
Kyrgyzstan
O. S. Lunegova
National Center of Cardiology and Therapy named after academician MIrsaid
Mirrahimov
Kyrgyzstan
Kyrgyzstan
B. Z. Imanov
National Center of Cardiology and Therapy named after academician MIrsaid
Mirrahimov
Kyrgyzstan
Kyrgyzstan
M. A. Pavlenko
Kyrghyz-Russian Slavic University; Bishkek
Kyrgyzstan
Kyrgyzstan
A. E. Mirrahimov
Kyrghyz-Russian Slavic University; Bishkek
Kyrgyzstan
Kyrgyzstan
I. JU. Gottfried
National Center of Cardiology and Therapy named after academician MIrsaid
Mirrahimov
Kyrgyzstan
Kyrgyzstan
E. M. Mirrahimov
Kyrgyz State Medical Academy, Akhunbaeva ul. 92, Bishkek, 720020 Kyrgyz Republic
Kyrgyzstan
Kyrgyzstan
References
1. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9.
2. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
3. Salonen J.R., Salonen R. Ultrasonographicaly assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11(5):1245-9.
4. Jashnani K.D., Kulkarni R.R., Deshpande J.R. Role of carotid intimamedia thickness in assessment of atherosclerosis: an autopsy study. Indian Heart J 2005;57(4):319-23.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.
6. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.
7. European Carotid Surgery Trialists` Collaborative Group. MRC – European Carotid Surgery Trial: interim results for symptomatic patients with severe (70 – 99%) or with mild (0 – 29%) carotid stenosis. Lancet 1991; 337(8752):1235-43.
8. Downs J.R., Clearfield M., Tyroler H.A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-9.
9. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 2004;291:1071-80.
10. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
11. Lorenz M.W., von Kegler S., Steinmetz H., et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37:87-92.
12. Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39(6):1020-5.
13. Mital S., Liao J.K. Statins and the myocardium. Semin Vasc Med 2004;4:377-84.
14. Hasegawa H., Yamamoto R., Takano H., et al. 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003;35(8):953–960.
15. Nishikawa H., Miura S., Zhang B., et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004;68(2):121- 5.
16. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-7.
Review
For citations:
Kerimkulova A.S., Noruzbaeva A.M., Lunegova O.S., Imanov B.Z., Pavlenko M.A., Mirrahimov A.E., Gottfried I.J., Mirrahimov E.M. LOVASTATIN EFFECT ON VASCULAR REMODELING AND MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2008;4(4):18-22. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-18-22
Views:
613
Email this article 